基于英国群岛狼疮评估组的复合狼疮评估应答在中重度系统性红斑狼疮患者报告结局中的临床意义:阿尼鲁单抗3期TULIP-1和TULIP-2试验的事后分析
该事后分析纳入TULIP-1和TULIP-2两项3期试验的726例中重度SLE患者,比较BICLA应答者与非应答者在患者报告结局上的差异。结果显示BICLA应答者在患者总体评估、健康相关生活质量、疲劳和疼痛方面较非应答者报告更大改善,且接受阿尼鲁单抗300mg治疗者中BICLA应答者比例更高、患者报告结局改善更多。
要点
- BICLA应答者较非应答者在患者总体评估、SF-36、狼疮生活质量、FACIT-F疲劳和疼痛数字评定量表上报告更大改善。
- BICLA应答者中达到各SF-36域和FACIT-F最小临床重要差异及正常参考值的比例均高于非应答者。
- 接受阿尼鲁单抗300mg治疗者较安慰剂组在患者报告结局上报告更大的数值改善。
核心结论
- BICLA应答者较BICLA非应答者在患者总体评估、健康相关生活质量、疲劳和疼痛方面报告显著且有临床意义的改善。
- 接受阿尼鲁单抗治疗的中重度SLE患者中,BICLA应答者比例更高且健康相关生活质量、疲劳和疼痛改善更多。
研究设计与样本
- 对3期TULIP-1(NCT02446912)和TULIP-2(NCT02446899)阿尼鲁单抗试验的汇总数据进行事后分析。
- 共纳入726例患者,其中366例接受安慰剂(TULIP-1 184例,TULIP-2 182例),360例接受静脉阿尼鲁单抗300mg(每项试验各180例)。
- 患者平均年龄41.8岁(SD 11.9),女性674例(93%),男性52例(7%),白人479例(66%)。
- BICLA应答者283例(39%),BICLA非应答者443例(61%)。
- 采用SF-36第2版、狼疮生活质量量表、FACIT-F疲劳量表、疼痛数字评定量表和患者总体评估评估患者报告结局。
主要发现
- 第52周时,BICLA应答者较非应答者在患者总体评估、SF-36、狼疮生活质量、FACIT-F和疼痛数字评定量表评分上报告更大的平均基线改善(所有名义p<0.0053)。
- 达到SF-36躯体成分总结最小临床重要差异的比例:应答者165/277(60%)vs 非应答者63/416(15%)。
- 达到SF-36心理成分总结最小临床重要差异的比例:应答者140/276(51%)vs 非应答者59/416(15%)。
- 达到SF-36角色躯体最小临床重要差异的比例:应答者184/264(70%)vs 非应答者76/398(19%)。
- 达到FACIT-F最小临床重要差异的比例:应答者155/276(56%)vs 非应答者66/439(15%)。
关键数值与推荐
- 达到狼疮生活质量身体健康域最小临床重要差异的比例:应答者151/262(58%)vs 非应答者60/396(15%)。
- 达到狼疮生活质量亲密关系域最小临床重要差异的比例:应答者77/187(41%)vs 非应答者33/286(11%)。
- 第52周时BICLA应答者中SF-36各域和FACIT-F评分达到或超过正常参考值的比例均高于BICLA非应答者。
- 接受阿尼鲁单抗治疗者较接受安慰剂者在患者总体评估、SF-36、狼疮生活质量、FACIT-F和疼痛数字评定量表评分上报告更大的数值改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) is a validated global measure of treatment response in systemic lupus erythematosus (SLE) clinical trials but does not include patient-reported outcomes. To evaluate the clinical meaningfulness of a BICLA response from the patient perspective, we aimed to analyse patient-reported outcomes by BICLA responses with anifrolumab or placebo in patients with moderate to severe SLE. METHODS: We did a post-hoc analysis of pooled data from the phase 3 TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) trials of anifrolumab, which assessed health-related quality of life using the Short Form 36 Health Survey (SF-36; version 2) and Lupus Quality of Life, fatigue using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), pain using the Numerical Rating Scale, and disease activity using Patient Global Assessment. Changes from baseline and proportions of patients reporting improvements in patient-reported outcomes greater than or equal to the minimum clinically important differences and scores greater than or equal to the normative values were compared in BICLA responders and non-responders and by treatment group (intravenous anifrolumab 300 mg or placebo). FINDINGS: 726 patients were included in the TULIP trials, of whom 366 received placebo (184 patients in TULIP-1 and 182 in TULIP-2) and 360 received anifrolumab 300 mg (180 patients in each trial). The mean patient age was 41·8 years (SD 11·9). 674 (93%) patients were female, 52 (7%) were male, and 479 (66%) were White; 283 (39%) were BICLA responders and 443 (61%) were BICLA non-responders. Compared with non-responders, BICLA responders reported greater mean improvements from baseline at week 52 in Patient Global Assessment, SF-36, Lupus Quality of Life, FACIT-F, and pain Numerical Rating Scale scores (all nominal p<0·0053). Compared with non-responders, a greater proportion of BICLA responders reported improvements greater than or equal to the minimum clinically important difference across all SF-36 domains; eg, Physical Component Summary (165 [60%] of 277 for responders vs 63 [15%] of 416 for non-responders), Mental Component Summary (140 [51%] of 276 vs 59 [15%] of 416), and role physical (184 [70%] of 264 vs 76 [19%] of 398); Lupus Quality of Life domains; eg, physical health (151 [58%] of 262 vs 60 [15%] of 396), and intimate relationships (77 [41%] of 187 vs 33 [11%] of 286), and FACIT-F (155 [56%] of 276 vs 66 [15%] of 439). Similarly, a greater proportion of BICLA responders had scores equal to or greater than the normative values across all SF-36 domains and FACIT-F compared with BICLA non-responders at week 52. Patients who received anifrolumab reported greater numerical improvements in Patient Global Assessment, SF-36, Lupus Quality of Life, FACIT-F, and pain Numerical Rating Scale scores than those who received placebo. INTERPRETATION: BICLA responders reported significant and clinically meaningful improvements in Patient Global Assessment, health-related quality of life, fatigue, and pain compared with BICLA non-responders. More patients with moderate to severe SLE who received anifrolumab were BICLA responders and had improved health-related quality of life, fatigue, and pain than those who received placebo. FUNDING: AstraZeneca.
引用
- Strand V, O'Quinn S, Furie RA, et al. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. Lancet Rheumatol. 2022. PMID: 38288936. doi:10.1016/S2665-9913(21)00387-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。